Neurogene Inc. (NGNE)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch NGNE
See up to 3 months of NGNE. The 7-day demo opens the 1M and 3M ranges and puts NGNE on your watchlist.
Start 7-day demoLatest NGNE insider trades
About Neurogene Inc. (NGNE)
Neurogene Inc. files with the SEC under CIK 0001404644 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
NGNE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Option exercise | 2 | 1,512 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
NGNE insider transactions (Form 4)
4025 Form 4 filings on record, the earliest from Nov 26, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Rachel McMinn - Officer | Option exercise | Common Stock | 756 | $25.32 | $19K | |
| Rachel McMinn - Officer | Option exercise | Stock Option (Right to Buy) | 756 | $0.00 | - | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 600 | $36.02 footnote F2 | $22K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 4,200 | $36.13 footnote F4 | $152K | |
| ||||||
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 739 | $34.06 footnote F2 | $25K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 2,531 | $34.58 footnote F4 | $88K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 1,530 | $35.23 footnote F5 | $54K | |
| ||||||
| Keith Woods - Director | Grant or award | Stock Option (Right to Buy) | 15,400 | $0.00 | - | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 4,800 | $30.07 footnote F2 | $144K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 4,800 | $32.44 footnote F4 | $156K | |
| ||||||
 Christina Shafer - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 120,000 | $0.00 | - | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 2,558 | $21.62 footnote F2 | $55K | |
| ||||||
| Rachel McMinn - Officer | Open-market sale | Common Stock | 3,352 footnote F2 | $22.07 | $74K | |
| ||||||
 Julie Jordan - Officer | Open-market sale | Common Stock | 828 | $21.89 footnote F2 | $18K | |
| ||||||
| Stuart Cobb - Officer | Open-market sale | Common Stock | 148 | $22.08 footnote F5 | $3K | |
| Stuart Cobb - Officer | Open-market sale | Common Stock | 3,991 | $20.41 footnote F2 | $81K | |
| Stuart Cobb - Officer | Open-market sale | Common Stock | 2,658 | $21.34 footnote F4 | $57K | |
| ||||||
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 263 | $22.02 footnote F5 | $6K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 2,387 | $20.42 footnote F2 | $49K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 1,395 | $21.25 footnote F4 | $30K | |
| ||||||
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 4,800 | $25.11 footnote F2 | $121K | |
| ||||||
| Stuart Cobb - Officer | Grant or award | Common Stock | 16,500 footnote F1 | $0.00 | - | |
| ||||||
| Julie Jordan - Officer | Grant or award | Common Stock | 4,900 footnote F1 | $0.00 | - | |
| Julie Jordan - Officer | Grant or award | Stock Option (Right to Buy) | 29,600 | $0.00 | - | |
| ||||||
| Christine Mikail Cvijic - Officer | Grant or award | Common Stock | 22,000 footnote F1 | $0.00 | - | |
| Christine Mikail Cvijic - Officer | Grant or award | Stock Option (Right to Buy) | 131,900 | $0.00 | - | |
| ||||||
| Rachel McMinn - Officer | Grant or award | Common Stock | 25,900 footnote F1 | $0.00 | - | |
| Rachel McMinn - Officer | Grant or award | Stock Option (Right to Buy) | 155,100 | $0.00 | - | |
| ||||||
 Rohan Palekar - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Robert Baffi - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Sarah B. Noonberg - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Cory S. Freedland - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Keith Woods - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Robert Baffi - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Samsara BioCapital GP, LLC | Open-market purchase | Common Stock | 20,748 | $24.91 | $517K | |
| Samsara BioCapital GP, LLC | Open-market purchase | Common Stock | 10,803 | $26.01 | $281K | |
| Samsara BioCapital GP, LLC | Open-market purchase | Common Stock | 15,219 | $26.73 | $407K | |
| Samsara BioCapital GP, LLC | Open-market purchase | Common Stock | 2,000 | $27.50 | $55K | |
| Christine Mikail Cvijic - Officer | Open-market purchase | Common Stock | 24,000 | $20.48 | $491K | |
| Rachel McMinn - Officer | Open-market purchase | Common Stock | 47,500 | $20.40 | $969K | |
Item 2.02, 9.01
Item 1.01, 8.01, 9.01
Item 7.01, 8.01, 9.01
Item 7.01, 9.01
Recent NGNE Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
NGNE insider trading FAQ
What is the latest insider trade for NGNE?
Neurogene Inc. (NGNE) had 1 insider filing in the last 90 days, with the most recent on 2026-10-02. The full record for NGNE runs to 25 Form 4 filings, the earliest from 2024-11-26. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NGNE stock?
No insider purchases of NGNE were filed in the last 90 days. 6 purchases are on record for this company.
How many insiders are selling NGNE stock?
No insider sales of NGNE were filed in the last 90 days. 17 sales are on record for this company.
Where can I see NGNE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NGNE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Rachel McMinn view on EDGAR
- - Christine Mikail Cvijic view on EDGAR
- - Christine Mikail Cvijic view on EDGAR
- - Keith Woods view on EDGAR
- - Christine Mikail Cvijic view on EDGAR
- - Christina Shafer view on EDGAR
- - Christine Mikail Cvijic view on EDGAR
- - Rachel McMinn view on EDGAR
- - Julie Jordan view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where NGNE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NGNE with a 7-day demo
- NGNE on your watchlist
- Every NGNE Form 4 filing on record
- Up to 3 months of NGNE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
